Guggenheim lowered the firm’s price target on Sanofi (SNY) to EUR 101 from EUR 104 and keeps a Buy rating on the shares after updating the firm’s model ahead of Q3 results following a check-in with IR. The firm also notes there has been increasing interest from investors on the possibility of a Dupixent settlement that could extend the product loss of exclusivity beyond the assumed current expiration in the wake of a series of recent patent settlements.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Novavax’s Nuvaxovid EU approval triggers $25M milestone payment from Sanofi
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- Revvity announces program to expand type 1 diabetes offering
- Nike reports Q1 beat, U.S. takes 5% stake in Lithium Americas: Morning Buzz